Thei intraoperative fluorecescene fluore by means of the indocyanine green and near infrated optical imaging

MUTO Jun0 sites300 target enrollmentSeptember 2, 2019

Overview

No summary available.

Registry

who.int

Start Date

September 2, 2019

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

MUTO Jun

•The following patients WILL BE included in the study
•1\.Those who are diagnosed to have brain or spinal tumor by CT scan or MRI
•2\. Those who do not possess any serious hematological and renal conditions, physical examination findings, and past medical history including familial history
•3\.Those who are be able to sign a written informed consent. However, if incapacitated, a legal surrogate may consent on his/her behalf
•4\. Those who are younger 18 years and older 75 years of age, regardless of gender; and
•5\. Those who will undergo surgical treatment.

•The following patients WILL BE excluded FROM the study
•1\. Those who have an allergy for iodine
•2\. Those who have a creatine clearance of lower 30 mL .min (Cockroft\-Gault)
•3\. Those who are taking biguanides for diabetes mellitus
•4\. Those who have dementia or any psychiatric disease
•5\. Those who have a concomitant hepatic dysfunction, Gamma GTP more than 100, proton\-beam time less than 60%, bilirubin more than 51 micro mol. L
•6\. Those who are pregnant
•7\. Those who are receiving hemodialysis treatment
•8\.Those who do not consent, may remove this part since it was already mentioned in the inclusion
•9\. Those who will be undergoing further examinations, other than the present study, necessitating iodine contrast, to avoid potential toxicity